Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts

Annals of Thoracic Surgery

Volumn 78, Issue 2, 2004, Pages 436-443

  Beseth, Bryce D ^a   Cameron, Robert B ^a,f   Leland, Pamela ^b   You, Liang ^a   Varricchio, Frederick ^c   Kreitman, Robert J ^d   Maki, Richard A ^e   Jablons, David M ^a   Husain, Syed R ^b   Puri, Raj K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Center for Biologics Evaluation/Res   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NEUROCRINE BIOSCIENCES INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

14

Indexed keywords

CYTOTOXIN; INTERLEUKIN 4 RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL INTERACTION; CELL LINE; CELL SURFACE; CELL SURVIVAL; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RADIORECEPTOR ASSAY; TUMOR VOLUME; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; AGED; ANIMALS; BACTERIAL TOXINS; CELL LINE, TUMOR; EXOTOXINS; FEMALE; HUMANS; IMMUNOTOXINS; INTERLEUKIN-4; MALE; MESOTHELIOMA; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM PROTEINS; PLEURAL NEOPLASMS; RECEPTORS, INTERLEUKIN-4; SPECIFIC PATHOGEN-FREE ORGANISMS; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3242815209     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2004.03.010     Document Type: Article

References (30)

1. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol. 145:1997;211-218
2. Perkins R.C., Broaddus V.C., Shetty S., Hamilton S., Idell S. Asbestos upregulates expression of the urokinase-type plasminogen activator receptor on mesothelioma cells. Am J Respiratory Cell Mol Biol. 21:1999;637-646
3. Peto J., Decarli A., La Vecchia C., et al. The European mesothelioma epidemic. Br J Cancer. 79:1999;666-672
4. Konig J.E., Tolneay E., Wiethege T., Muller K.M. Co-expression of vascular endothelial growth factor (VEGF) and its receptor f/t-1 in malignant pleural mesothelioma. Respiration. 67:2000;36-40
5. Kumar-Singh S., Weyler J., Martin M.J.H., Vermeulen P.B., Van Marck E. Angiogenic cytokines in mesothelioma a study of VEGF, FGF-1 and -2 and TGF beta expression. J Pathol. 189:1999;72-78
6. Faux S.P., Houghton C.E., Hubbard A., Patrick G. Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres. Carcinogenesis. 21:2000;2275-2280
7. Gessner A., Rollinghoff M. Biologic functions and signaling of the interleukin-4 receptor complexes. Immunobiology. 201:2000;285-307
8. Howard M., Farrar J., Hilfiker M., et al. Identification of a T-cell derived B cell growth factor distinct from interleukin 2. J Exp Med. 155:1982;914-923
9. Chomarat P, Banchereau. An update on interleukin-4 and its receptor. Eur Cytokine Netw 1997;8:333-44
10. Puri R.K., Siegel J.P. Interleukin-4 and cancer therapy. Cancer Inv. 11:1993;473-486
11. Puri R.K., Leland P., Kreitman R.J., Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer. 58:1994;574-581
12. Varricchio F., Husain S.R., Leland P., Gill P., Puri R.K. Interleukin-4 receptor expression in vivo on human AIDS-related Kaposi's sarcoma. Oncol Res. 9:1997;495-503
13. Hoon D.S.B., Banex M., Okun E., et al. Modulation of human melanoma cells by interleukin-4 and in combination with γ-interferon or α-tumor necrosis factor. Cancer Res. 51:1991;2002-2008
14. Topp M.S., Koenigsman M., Anthony M., et al. Recombinant interleukin-4 inhibits growth of some human lung tumor cell lines in vitro, and in vivo. Blood. 82:1993;2837-2844
15. Obiri N.I., Hillman G., Haas G.O., Sud S., Puri R.K. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest. 91:1993;88-93
16. Toi M., Bicknel R., Harris A.L. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 52:1992;275-279
17. Essner R., Huynh Y., Nguyen T., Morton D.L., Hoon D.S. Functional interleukin 4 receptor and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers novel targets for immune therapy. J Thorac Cardiovasc Surg. 119:2000;10-20
18. Puri R.K., Hoon D.S., Leland P., et al. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. 56:1996;5631-5637
19. Husain S.R., Kreitman R.J., Pastan I., Puri R.K. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med. 5:1999;817-822
20. Leland P., Taguchi J., Husain S.R., Kreitman R.J., Pastan I., Puri R.K. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4 Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol Med. 6:2000;165-178
21. Husain S.R., Behari N., Kreitman R.J., Pastan I., Puri R.K. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res. 58:1998;3649-3653
22. Kreitaman R.J., Puri R.K., Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci. 91:1994;6889-6893
23. Puri R.K., Finbloom D.S., Leland P., Mostowski H., Siegel J.P. Expression of high-affinity IL-4 receptors on murine tumor infiltrating lymphocytes and their up-regulation by IL-2. Immunology. 70:1990;492-497
24. Husain S.R., Leland P., Aggarwal B.B., Puri R.K. Transcriptional up-regulation of interleukin 4 receptors by human immunodeficiency virus type 1 tat gene. AIDS Res Hum Retroviruses. 12:1996;1349-1359
25. Muson P.J., Rodbard D. Ligand a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 107:1980;220-239
26. Puri R.K., Ogata M., Leland P., Feldman G.M., Pastan I. Expression of high affinity IL-4 receptors on murine sarcoma cells and receptor mediated cytotoxicity of tumor cells to chimeric protein between IL-4 and Pseudomonas exotoxin. Cancer Res. 51:1991;3011-3017
27. Kreitman R.J., Puri R.K., Pastan I. Increased antitumor activity of a circularly permuted recombinant interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res. 55:1995;3357-3363
28. Kawakami K., Kawakami M., Puri R.K. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol. 21:2001;299-310
29. Kreitman R.J. Immunotoxins in cancer therapy. Curr Opin Immunol. 11:1999;570-578
30. Van Kroonenburgh M.J., Pauwels E.K. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun. 11:1988;919-930